July 1, 2016 / 2:32 PM / in a year

BUZZ-Aeterna Zentaris Inc: Licenses lead drug

** Drug developer’s U.S.-listed shares up 15 pct at $3.75

** Company says signed license agreement with Orient EuroPharma’s unit for commercializing its lead experimental anti-cancer drug, Zoptrex, in Taiwan and nine countries in Southeast Asia

** Company will also license intellectual property related to Zoptrex

** Orient has also agreed to make additional payments and royalties to the company upon achieving regulatory and commercial milestone

** Up to Friday’s close, stock had fallen 27 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below